131 results on '"Kidd, Sarah"'
Search Results
2. Update on methods used for mycological testing: wide diversity and opportunities for improvement persist.
- Author
-
Morris AJ, Kidd SE, Halliday CL, C-A Chen S, McKinney W, Ryan K, and Elvy J
- Abstract
Past analysis of laboratory methods used for mycology specimens revealed significant variation in practices, many of which fell short of recommended procedures. In 2016 these findings led to a set of recommendations for laboratories to consider modification of their methods where appropriate, to analyse current laboratory methods used by participants in the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) Mycology module, and to compare these to the 2016 recommendations. Seven test items, with 105-107 participants each, were analysed. Several laboratories (7-12%) did not handle specimens as recommended in an appropriate biological safety cabinet. Direct microscopy was not performed on tissue specimens 23-25% of the time. The most used staining method was potassium hydroxide with an optical brightener for fluorescent microscopy (49%) followed by Gram stain (33%). While 17-25% of laboratories used three or more media, use of four or more was uncommon (<3%). Between 9-13% of participants used only a single non-inhibitory medium for cultures. Urine specimens were incubated longer than recommended with 57% of laboratories incubating for >7days and 24% >21 days. Duration of incubation was shorter than recommended for several specimen types with 36% of skin specimens and 37-48% of tissue specimens being kept ≤21 days. For cultures kept >7 days, 13% were inspected daily but for those incubating >14 days only 3%. The methods of several laboratories remain outside recommended practice. An updated set of recommendations are made., (Copyright © 2024 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Photo Quiz: Subungual organism in a renal transplant patient.
- Author
-
Crawford LC and Kidd SE
- Subjects
- Humans, Male, Middle Aged, Transplant Recipients, Nails microbiology, Nails pathology, Onychomycosis diagnosis, Onychomycosis microbiology, Onychomycosis pathology, Kidney Transplantation adverse effects
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
4. Candida tropicalis-A systematic review to inform the World Health Organization of a fungal priority pathogens list.
- Author
-
Keighley C, Kim HY, Kidd S, Chen SC, Alastruey A, Dao A, Bongomin F, Chiller T, Wahyuningsih R, Forastiero A, Al-Nuseirat A, Beyer P, Gigante V, Beardsley J, Sati H, Morrissey CO, and Alffenaar JW
- Subjects
- Humans, Candidiasis, Invasive epidemiology, Candidiasis, Invasive microbiology, Candidiasis, Invasive drug therapy, Candidiasis, Invasive mortality, Incidence, Global Health, Risk Factors, Candida tropicalis drug effects, Candida tropicalis isolation & purification, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, World Health Organization, Drug Resistance, Fungal
- Abstract
In response to the growing global burden of fungal infections with uncertain impact, the World Health Organization (WHO) established an Expert Group to identify priority fungal pathogens and establish the WHO Fungal Priority Pathogens List for future research. This systematic review aimed to evaluate the features and global impact of invasive candidiasis caused by Candida tropicalis. PubMed and Web of Science were searched for studies reporting on criteria of mortality, morbidity (defined as hospitalization and disability), drug resistance, preventability, yearly incidence, diagnostics, treatability, and distribution/emergence from 2011 to 2021. Thirty studies, encompassing 436 patients from 25 countries were included in the analysis. All-cause mortality due to invasive C. tropicalis infections was 55%-60%. Resistance rates to fluconazole, itraconazole, voriconazole and posaconazole up to 40%-80% were observed but C. tropicalis isolates showed low resistance rates to the echinocandins (0%-1%), amphotericin B (0%), and flucytosine (0%-4%). Leukaemia (odds ratio (OR) = 4.77) and chronic lung disease (OR = 2.62) were identified as risk factors for invasive infections. Incidence rates highlight the geographic variability and provide valuable context for understanding the global burden of C. tropicalis infections. C. tropicalis candidiasis is associated with high mortality rates and high rates of resistance to triazoles. To address this emerging threat, concerted efforts are needed to develop novel antifungal agents and therapeutic approaches tailored to C. tropicalis infections. Global surveillance studies could better inform the annual incidence rates, distribution and trends and allow informed evaluation of the global impact of C. tropicalis infections., (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
5. Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.
- Author
-
Asogan M, Kim HY, Kidd S, Alastruey-Izquierdo A, Govender NP, Dao A, Shin JH, Heim J, Ford NP, Gigante V, Sati H, Morrissey CO, Alffenaar JW, and Beardsley J
- Subjects
- Humans, Incidence, Candidiasis epidemiology, Candidiasis microbiology, Cross Infection epidemiology, Cross Infection microbiology, Candida parapsilosis drug effects, Drug Resistance, Fungal, World Health Organization, Antifungal Agents therapeutic use, Antifungal Agents pharmacology
- Abstract
Candida parapsilosis is globally distributed and recognised for causing an increasing proportion of invasive Candida infections. It is associated with high crude mortality in all age groups. It has been particularly associated with nosocomial outbreaks, particularly in association with the use of invasive medical devices such as central venous catheters. Candida parapsilosis is one of the pathogens considered in the WHO priority pathogens list, and this review was conducted to inform the ranking of the pathogen in the list. In this systematic review, we searched PubMed and Web of Science to find studies between 2011 and 2021 reporting on the following criteria for C. parapsilosis infections: mortality, morbidity (hospitalisation and disability), drug resistance, preventability, yearly incidence, and distribution/emergence. We identified 336 potentially relevant papers, of which 51 were included in the analyses. The included studies confirmed high mortality rates, ranging from 17.5% to 46.8%. Data on disability and sequelae were sparse. Many reports highlighted concerns with azole resistance, with resistance rates of >10% described in some regions. Annual incidence rates were relatively poorly described, although there was clear evidence that the proportion of candidaemia cases caused by C. parapsilosis increased over time. While this review summarises current data on C.parapsilosis, there remains an urgent need for ongoing research and surveillance to fully understand and manage this increasingly important pathogen., (© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
6. Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.
- Author
-
Kim HY PhD, Nguyen TA MSc, Kidd S PhD, Chambers J MD, Alastruey-Izquierdo A PhD, Shin JH MD, Dao A PhD, Forastiero A MD, Wahyuningsih R MD, Chakrabarti A MD, Beyer P, Gigante V PhD, Beardsley J PhD, Sati H PhD, Morrissey CO PhD, and Alffenaar JW PhD
- Subjects
- Humans, Microbial Sensitivity Tests, Candidemia epidemiology, Candidemia microbiology, Candidemia drug therapy, Disease Outbreaks, Candida drug effects, Candida classification, Candida isolation & purification, Incidence, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Drug Resistance, Fungal, World Health Organization, Candidiasis microbiology, Candidiasis epidemiology, Candidiasis drug therapy, Candida auris drug effects
- Abstract
The World Health Organization (WHO) in 2022 developed a fungal priority pathogen list. Candida auris was ultimately ranked as a critical priority pathogen. PubMed and Web of Science were used to find studies published from 1 January 2011 to 18 February 2021, reporting on predefined criteria including: mortality, morbidity (i.e., hospitalization and disability), drug resistance, preventability, yearly incidence, and distribution/emergence. Thirty-seven studies were included in the final analysis. The overall and 30-day mortality rates associated with C. auris candidaemia ranged from 29% to 62% and 23% to 67%, respectively. The median length of hospital stay was 46-68 days, ranging up to 140 days. Late-onset complications of C. auris candidaemia included metastatic septic complications. Resistance rates to fluconazole were as high as 87%-100%. Susceptibility to isavuconazole, itraconazole, and posaconazole varied with MIC90 values of 0.06-1.0 mg/l. Resistance rates to voriconazole ranged widely from 28% to 98%. Resistance rates ranged between 8% and 35% for amphotericin B and 0%-8% for echinocandins. Over the last ten years, outbreaks due to C. auris have been reported in in all WHO regions. Given the outbreak potential of C. auris, the emergence and spread of MDR strains, and the challenges associated with its identification, and eradication of its environmental sources in healthcare settings, prevention and control measures based on the identified risk factors should be evaluated for their effectiveness and feasibility. Global surveillance studies could better inform the incidence rates and distribution patterns to evaluate the global burden of C. auris infections., (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
7. Candida glabrata (Nakaseomyces glabrata): A systematic review of clinical and microbiological data from 2011 to 2021 to inform the World Health Organization Fungal Priority Pathogens List.
- Author
-
Beardsley J, Kim HY, Dao A, Kidd S, Alastruey-Izquierdo A, Sorrell TC, Tacconelli E, Chakrabarti A, Harrison TS, Bongomin F, Gigante V, Galas M, Siswanto S, Dagne DA, Roitberg F, Sati H, Morrissey CO, and Alffenaar JW
- Subjects
- Humans, Candidiasis epidemiology, Candidiasis microbiology, Candidiasis drug therapy, Global Health, Incidence, Candida glabrata drug effects, Candida glabrata isolation & purification, Drug Resistance, Fungal, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, World Health Organization
- Abstract
Recognising the growing global burden of fungal infections, the World Health Organization (WHO) established an advisory group consisting of experts in fungal diseases to develop a Fungal Priority Pathogen List. Pathogens were ranked based on their research and development needs and perceived public health importance using a series of global surveys and pathogen characteristics derived from systematic reviews. This systematic review evaluates the features and global impact of invasive disease caused by Candida glabrata (Nakaseomyces glabrata). PubMed and Web of Science were searched for studies reporting on mortality, morbidity (hospitalization and disability), drug resistance (including isolates from sterile and non-sterile sites, since these reflect the same organisms causing invasive infections), preventability, yearly incidence, diagnostics, treatability, and distribution/emergence in the last 10 years. Candida glabrata (N. glabrata) causes difficult-to-treat invasive infections, particularly in patients with underlying conditions such as immunodeficiency, diabetes, or those who have received broad-spectrum antibiotics or chemotherapy. Beyond standard infection prevention and control measures, no specific preventative measures have been described. We found that infection is associated with high mortality rates and that there is a lack of data on complications and sequelae. Resistance to azoles is common and well described in echinocandins-in both cases, the resistance rates are increasing. Candida glabrata remains mostly susceptible to amphotericin and flucytosine. However, the incidence of the disease is increasing, both at the population level and as a proportion of all invasive yeast infections, and the increases appear related to the use of antifungal agents., (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
8. Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens.
- Author
-
Nguyen TA, Kim HY, Stocker S, Kidd S, Alastruey-Izquierdo A, Dao A, Harrison T, Wahyuningsih R, Rickerts V, Perfect J, Denning DW, Nucci M, Cassini A, Beardsley J, Gigante V, Sati H, Morrissey CO, and Alffenaar JW
- Subjects
- Humans, Incidence, Risk Factors, Candidiasis epidemiology, Candidiasis microbiology, Candidiasis prevention & control, Drug Resistance, Fungal, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, World Health Organization, Pichia isolation & purification, Pichia drug effects
- Abstract
In response to the growing global threat of fungal infections, in 2020 the World Health Organisation (WHO) established an Expert Group to identify priority fungi and develop the first WHO fungal priority pathogen list (FPPL). The aim of this systematic review was to evaluate the features and global impact of invasive infections caused by Pichia kudriavzevii (formerly known as Candida krusei). PubMed and Web of Science were used to identify studies published between 1 January 2011 and 18 February 2021 reporting on the criteria of mortality, morbidity (defined as hospitalisation and length of stay), drug resistance, preventability, yearly incidence, and distribution/emergence. Overall, 33 studies were evaluated. Mortality rates of up to 67% in adults were reported. Despite the intrinsic resistance of P. kudriavzevii to fluconazole with decreased susceptibility to amphotericin B, resistance (or non-wild-type rate) to other azoles and echinocandins was low, ranging between 0 and 5%. Risk factors for developing P. kudriavzevii infections included low birth weight, prior use of antibiotics/antifungals, and an underlying diagnosis of gastrointestinal disease or cancer. The incidence of infections caused by P. kudriavzevii is generally low (∼5% of all Candida-like blood isolates) and stable over the 10-year timeframe, although additional surveillance data are needed. Strategies targeting the identified risk factors for developing P. kudriavzevii infections should be developed and tested for effectiveness and feasibility of implementation. Studies presenting data on epidemiology and susceptibility of P. kudriavzevii were scarce, especially in low- and middle-income countries (LMICs). Thus, global surveillance systems are required to monitor the incidence, susceptibility, and morbidity of P. kudriavzevii invasive infections to inform diagnosis and treatment. Timely species-level identification and susceptibility testing should be conducted to reduce the high mortality and limit the spread of P. kudriavzevii in healthcare facilities., (© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
9. Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
- Author
-
Dao A, Kim HY, Garnham K, Kidd S, Sati H, Perfect J, Sorrell TC, Harrison T, Rickerts V, Gigante V, Alastruey-Izquierdo A, Alffenaar JW, Morrissey CO, Chen SC, and Beardsley J
- Subjects
- Humans, Microbial Sensitivity Tests, Cryptococcosis epidemiology, Cryptococcosis microbiology, Cryptococcosis mortality, Antifungal Agents therapeutic use, Antifungal Agents pharmacology, Cryptococcus gattii drug effects, Cryptococcus neoformans drug effects, Cryptococcus neoformans isolation & purification, Drug Resistance, Fungal, World Health Organization
- Abstract
Cryptococcosis causes a high burden of disease worldwide. This systematic review summarizes the literature on Cryptococcus neoformans and C. gattii infections to inform the World Health Organization's first Fungal Priority Pathogen List. PubMed and Web of Science were used to identify studies reporting on annual incidence, mortality, morbidity, antifungal resistance, preventability, and distribution/emergence in the past 10 years. Mortality rates due to C. neoformans were 41%-61%. Complications included acute renal impairment, raised intracranial pressure needing shunts, and blindness. There was moderate evidence of reduced susceptibility (MIC range 16-32 mg/l) of C. neoformans to fluconazole, itraconazole, ketoconazole, voriconazole, and amphotericin B. Cryptococcus gattii infections comprised 11%-33% of all cases of invasive cryptococcosis globally. The mortality rates were 10%-23% for central nervous system (CNS) and pulmonary infections, and ∼43% for bloodstream infections. Complications described included neurological sequelae (17%-27% in C. gattii infections) and immune reconstitution inflammatory syndrome. MICs were generally low for amphotericin B (MICs: 0.25-0.5 mg/l), 5-flucytosine (MIC range: 0.5-2 mg/l), itraconazole, posaconazole, and voriconazole (MIC range: 0.06-0.5 mg/l). There is a need for increased surveillance of disease phenotype and outcome, long-term disability, and drug susceptibility to inform robust estimates of disease burden., (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
10. Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.
- Author
-
Neoh CF, Chen SC, Lanternier F, Tio SY, Halliday CL, Kidd SE, Kong DCM, Meyer W, Hoenigl M, and Slavin MA
- Subjects
- Humans, Drug Resistance, Fungal, Mycoses drug therapy, Mycoses diagnosis, Mycoses microbiology, Invasive Fungal Infections drug therapy, Invasive Fungal Infections diagnosis, Ascomycota classification, Ascomycota drug effects, Antifungal Agents therapeutic use, Scedosporium drug effects, Scedosporium classification
- Abstract
SUMMARYAlthough Scedosporium species and Lomentospora prolificans are uncommon causes of invasive fungal diseases (IFDs), these infections are associated with high mortality and are costly to treat with a limited armamentarium of antifungal drugs. In light of recent advances, including in the area of new antifungals, the present review provides a timely and updated overview of these IFDs, with a focus on the taxonomy, clinical epidemiology, pathogenesis and host immune response, disease manifestations, diagnosis, antifungal susceptibility, and treatment. An expansion of hosts at risk for these difficult-to-treat infections has emerged over the last two decades given the increased use of, and broader population treated with, immunomodulatory and targeted molecular agents as well as wider adoption of antifungal prophylaxis. Clinical presentations differ not only between genera but also across the different Scedosporium species. L. prolificans is intrinsically resistant to most currently available antifungal agents, and the prognosis of immunocompromised patients with lomentosporiosis is poor. Development of, and improved access to, diagnostic modalities for early detection of these rare mold infections is paramount for timely targeted antifungal therapy and surgery if indicated. New antifungal agents (e.g., olorofim, fosmanogepix) with novel mechanisms of action and less cross-resistance to existing classes, availability of formulations for oral administration, and fewer drug-drug interactions are now in late-stage clinical trials, and soon, could extend options to treat scedosporiosis/lomentosporiosis. Much work remains to increase our understanding of these infections, especially in the pediatric setting. Knowledge gaps for future research are highlighted in the review., Competing Interests: C.F.N. has received a fellowship grant from Gilead Sciences Australia. S.C.-A.C. received untied research funding from MSD Australia and F2G outside of the submitted work. F.L. received speaker fees from Gilead, MSD, Pfizer, and F2G, and serves advisory board for F2G. S.Y.T. is supported by the University of Melbourne for her PhD and received a grant from Gilead Sciences for a project unrelated to the submitted work. S.E.K. received conference and travel funding from Pfizer, AusDiagnostics, received speaker fees from Pfizer, and serves advisory board for Gilead Sciences. D.C.M.K. received grants from F2G unrelated to the submitted work. M.H. received research funding from Gilead Sciences, Astellas, MSD, IMMY, Mundipharma, Pulmocide, Scynexis, F2G, and Pfizer—all outside of the submitted work. M.A.S. has been on data safety, adjudication or advisory committees for Gilead Sciences, F2G, Cidara, Takeda, Merck, Roche, and Pfizer; and received research funding from Gilead Sciences, Merck, and F2G unrelated to the submitted work. All other authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
11. Fungal Keratitis, Epidemiology and Outcomes in a Tropical Australian Setting.
- Author
-
Kim LN, Karthik H, Proudmore KE, Kidd SE, and Baird RW
- Abstract
Background: Fungal keratitis is an ophthalmic emergency that can cause visual impairment and blindness. We reviewed the epidemiology and clinical features of fungal keratitis in a tropical Australian setting., Objectives: To document the clinical and microbiological characteristics of fungal keratitis in an Australian tropical setting., Methods: A retrospective cohort study of patients with fungal keratitis from October 2014 to December 2022 was conducted at Royal Darwin Hospital, Northern Territory, Australia. We reviewed all patients with culture-proven fungal keratitis and their outcomes., Results: There were 31 patients identified. Aboriginal and Torres Strait Islander (ATSI) patients were of a significantly younger median age (28 years) compared to non-ATSI patients (42 years), and they also presented later to health care. Contact lens use and ocular trauma were the most common predisposing factors. Most patients presented with a corneal infiltrate and corneal epithelial defect, and the central visual axis was affected in 54% of patients. Curvularia spp. and Fusarium spp. were the commonest causative fungi (39% and 30% respectively)., Conclusions: Our series is different and reveals a wider range of fungal species identified over the 7 years of the study, in particular, a range of Curvularia spp. were detected. Access to eye health services in rural and remote settings is important, particularly for ATSI patients, as morbidity remains high.
- Published
- 2024
- Full Text
- View/download PDF
12. Neonate with a large neck mass.
- Author
-
Thompson JJ, Kidd S, and Winckworth LC
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2024
- Full Text
- View/download PDF
13. Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion.
- Author
-
Kidd SE, Hagen F, Halliday CL, Abdolrasouli A, Boekhout T, Crous PW, Ellis DH, Elvy J, Forrest GN, Groenewald M, Hahn RC, Houbraken J, Rodrigues AM, Scott J, Sorrell TC, Summerbell RC, Tsui CKM, Yurkov A, and Chen SC-A
- Abstract
Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
14. Disseminated Rasamsonia argillacea complex infection presenting as intraventricular brain hemorrhage in a German shepherd dog in Australia.
- Author
-
Skinner C, Allavena R, Hoffmann K, Kelly-Bosma M, Kidd S, and Thomson C
- Abstract
A German Shepherd Dog diagnosed with Rasamsonia argillacea based on fungal culture and DNA sequencing, is the first documented case in Australia, and the Southern Hemisphere. This species is part of R. argillacea complex, which is an emerging concern in immunocompromised human and veterinary patients. Intraventricular brain hemorrhage, noted on MRI, has not been reported previously in a dog with fungal encephalitis. The patient was euthanized due to progression of clinical signs before a final diagnosis was made, so no treatment was attempted in this case., (© 2024 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
15. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.
- Author
-
Thompson KM, Kalkowska DA, Kidd SE, Burns CC, and Badizadegan K
- Abstract
Delays in achieving polio eradication have led to ongoing risks of poliovirus importations that may cause outbreaks in polio-free countries. Because of the low, but non-zero risk of paralysis with oral poliovirus vaccines (OPVs), countries that achieve and maintain high national routine immunization coverage have increasingly shifted to exclusive use of inactivated poliovirus vaccine (IPV) for all preventive immunizations. However, immunization coverage within countries varies, with under-vaccinated subpopulations potentially able to sustain transmission of imported polioviruses and experience local outbreaks. Due to its cost, ease-of-use, and ability to induce mucosal immunity, using OPV as an outbreak control measure offers a more cost-effective option in countries in which OPV remains in use. However, recent polio outbreaks in IPV-only countries raise questions about whether and when IPV use for outbreak response may fail to stop poliovirus transmission and what consequences may follow from using OPV for outbreak response in these countries. We systematically reviewed the literature to identify modeling studies that explored the use of IPV for outbreak response in IPV-only countries. In addition, applying a model of the 2022 type 2 poliovirus outbreak in New York, we characterized the implications of using different OPV formulations for outbreak response instead of IPV. We also explored the hypothetical scenario of the same outbreak except for type 1 poliovirus instead of type 2. We find that using IPV for outbreak response will likely only stop outbreaks for polioviruses of relatively low transmission potential in countries with very high overall immunization coverage, seasonal transmission dynamics, and only if IPV immunization interventions reach some unvaccinated individuals. Using OPV for outbreak response in IPV-only countries poses substantial risks and challenges that require careful consideration, but may represent an option to consider for some outbreaks in some populations depending on the properties of the available vaccines and coverage attainable., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kid Risk authors (KMT, DAK, KB) reports financial support was provided by Centers for Disease Control and Prevention. Kid Risk authors (KMT, DAK, KB) reports a relationship with Centers for Disease Control and Prevention that includes: funding grants., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. Surveillance for Acute Flaccid Myelitis - United States, 2018-2022.
- Author
-
Whitehouse ER, Lopez A, English R, Getachew H, Ng TFF, Emery B, Rogers S, and Kidd S
- Subjects
- Child, Humans, United States epidemiology, Paralysis, Neuromuscular Diseases epidemiology, Myelitis epidemiology, Central Nervous System Viral Diseases epidemiology, Enterovirus Infections epidemiology, Enterovirus D, Human
- Abstract
Acute flaccid myelitis (AFM) is a serious neurologic condition primarily affecting children; AFM can cause acute respiratory failure and permanent paralysis. AFM is a rare but known complication of various viral infections, particularly those of enteroviruses (EVs). Increases in AFM cases during 2014, 2016, and 2018 were associated with EV-D68 infection. This report examines trends in confirmed AFM cases during 2018-2022 and patients' clinical and laboratory characteristics. The number of AFM cases was low during 2019-2022 (28-47 cases per year); the number of cases remained low in 2022 despite evidence of increased EV-D68 circulation in the United States. Compared with cases during the most recent peak year (2018), fewer cases during 2019-2021 had upper limb involvement, prodromal respiratory or febrile illness, or cerebrospinal fluid pleocytosis, and more were associated with lower limb involvement. It is unclear why EV-D68 circulation in 2022 was not associated with an increase in AFM cases or when the next increase in AFM cases will occur. Nonetheless, clinicians should continue to suspect AFM in any child with acute flaccid limb weakness, especially those with a recent respiratory or febrile illness., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Published
- 2024
- Full Text
- View/download PDF
17. Multi-Locus Microsatellite Typing of Colonising and Invasive Aspergillus fumigatus Isolates from Patients Post Lung Transplantation and with Chronic Lung Disease.
- Author
-
Birnie JD, Ahmed T, Kidd SE, Westall GP, Snell GI, Peleg AY, and Morrissey CO
- Abstract
Aspergillus fumigatus can cause different clinical manifestations/phenotypes in lung transplant (LTx) recipients and patients with chronic respiratory diseases. It can also precipitate chronic lung allograft dysfunction (CLAD) in LTx recipients. Many host factors have been linked with the severity of A. fumigatus infection, but little is known about the contribution of different A. fumigatus strains to the development of different phenotypes and CLAD. We used multi-locus microsatellite typing (MLMT) to determine if there is a relationship between strain (i.e., genotype) and phenotype in 60 patients post LTx or with chronic respiratory disease across two time periods (1 November 2006-31 March 2009 and 1 November 2015-30 June 2017). The MLMT (STR Af ) assay was highly discriminatory (Simpson's diversity index of 0.9819-0.9942) with no dominant strain detected. No specific genotype-phenotype link was detected, but several clusters and related strains were associated with invasive aspergillosis (IA) and colonisation in the absence of CLAD. Host factors were linked to clinical phenotypes, with prior lymphopenia significantly more common in IA cases as compared with A. fumigatus -colonised patients (12/16 [75%] vs. 13/36 [36.1%]; p = 0.01), and prior Staphylococcus aureus infection was a significant risk factor for the development of IA (odds ratio 13.8; 95% confidence interval [2.01-279.23]). A trend toward a greater incidence of CMV reactivation post- A. fumigatus isolation was observed (0 vs. 5; p = 0.06) in LTx recipients. Further research is required to determine the pathogenicity and immunogenicity of specific A. fumigatus strains.
- Published
- 2024
- Full Text
- View/download PDF
18. Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
- Author
-
Kidd S, Clark T, Routh J, Cineas S, Bahta L, and Brooks O
- Subjects
- Adolescent, Adult, Humans, Advisory Committees, Immunization, New York, Poliovirus Vaccine, Oral adverse effects, United States epidemiology, Vaccination, Poliomyelitis epidemiology, Poliomyelitis prevention & control, Poliomyelitis etiology, Poliovirus, Poliovirus Vaccine, Inactivated adverse effects
- Abstract
Poliovirus can cause poliomyelitis and lifelong paralysis. Although wild poliovirus types 2 and 3 have been eradicated, wild poliovirus type 1 and vaccine-derived polioviruses are still circulating in multiple countries worldwide. In 2022, a case of paralytic polio caused by vaccine-derived poliovirus type 2 was identified in an unvaccinated young adult in New York. This case and subsequent detection of community transmission underscored the ongoing risk for importation of poliovirus into the United States and risk for poliomyelitis among unvaccinated persons. However, previous Advisory Committee on Immunization Practices (ACIP) recommendations for adult polio vaccination were limited to adults known to be at increased risk for exposure. During October 2022-June 2023, the ACIP Polio Vaccine Work Group reviewed data on poliovirus surveillance and epidemiology, safety and effectiveness of inactivated poliovirus vaccine (IPV), and other considerations outlined in the ACIP Evidence to Recommendations Framework. On June 21, 2023, ACIP voted to recommend that all U.S. adults aged ≥18 years who are known or suspected to be unvaccinated or incompletely vaccinated against polio complete a primary polio vaccination series with IPV. This report summarizes evidence considered for this recommendation and provides clinical guidance for the use of IPV in adults., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Published
- 2023
- Full Text
- View/download PDF
19. Invasive aspergillosis in adult patients in Australia and New Zealand: 2017-2020.
- Author
-
Tio SY, Chen SC, Hamilton K, Heath CH, Pradhan A, Morris AJ, Korman TM, Morrissey O, Halliday CL, Kidd S, Spelman T, Brell N, McMullan B, Clark JE, Mitsakos K, Hardiman RP, Williams P, Campbell AJ, Beardsley J, Van Hal S, Yong MK, Worth LJ, and Slavin MA
- Abstract
Background: New and emerging risks for invasive aspergillosis (IA) bring the need for contemporary analyses of the epidemiology and outcomes of IA, in order to improve clinical practice., Methods: The study was a retrospective, multicenter, cohort design of proven and probable IA in adults from 10 Australasian tertiary centres (January 2017-December 2020). Descriptive analyses were used to report patients' demographics, predisposing factors, mycological characteristics, diagnosis and management. Accelerated failure-time model was employed to determine factor(s) associated with 90-day all-cause mortality (ACM)., Findings: Of 382 IA episodes, 221 (in 221 patients) fulfilled inclusion criteria - 53 proven and 168 probable IA. Median patient age was 61 years (IQR 51-69). Patients with haematologic malignancies (HM) comprised 49.8% of cases. Fifteen patients (6.8%) had no pre-specified immunosuppression and eleven patients (5.0%) had no documented comorbidity. Only 30% of patients had neutropenia. Of 170 isolates identified, 40 (23.5%) were identified as non- Aspergillus fumigatus species complex. Azole-resistance was present in 3/46 (6.5%) of A. fumigatus sensu stricto isolates. Ninety-day ACM was 30.3%. HM (HR 1.90; 95% CI 1.04-3.46, p = 0.036) and ICU admission (HR 4.89; 95% CI 2.93-8.17, p < 0.001) but not neutropenia (HR 1.45; 95% CI 0.88-2.39, p = 0.135) were associated with mortality. Chronic kidney disease was also a significant predictor of death in the HM subgroup (HR 3.94; 95% CI 1.15-13.44, p = 0.028)., Interpretation: IA is identified in high number of patients with mild/no immunosuppression in our study. The relatively high proportion of non- A. fumigatus species complex isolates and 6.5% azole-resistance rate amongst A. fumigatus sensu stricto necessitates accurate species identification and susceptibility testing for optimal patient outcomes., Funding: This work is unfunded. All authors' financial disclosures are listed in detail at the end of the manuscript., Competing Interests: This work itself is not funded. All authors declare no conflicts of interest associated with this publication, or any financial support that could have influenced its outcome., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
20. Reply to "Re: Fungal Nomenclature: Managing Change Is the Name of the Game".
- Author
-
Kidd SE, Abdolrasouli A, and Hagen F
- Published
- 2023
- Full Text
- View/download PDF
21. An update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections.
- Author
-
Jenks JD, White PL, Kidd SE, Goshia T, Fraley SI, Hoenigl M, and Thompson GR 3rd
- Subjects
- Humans, Antifungal Agents therapeutic use, Pathology, Molecular, Fungi genetics, Sensitivity and Specificity, Mycoses diagnosis, Mycoses microbiology, Invasive Fungal Infections diagnosis
- Abstract
Background: Invasive fungal infections cause millions of infections annually, but diagnosis remains challenging. There is an increased need for low-cost, easy to use, highly sensitive and specific molecular assays that can differentiate between colonized and pathogenic organisms from different clinical specimens., Areas Covered: We reviewed the literature evaluating the current state of molecular diagnostics for invasive fungal infections, focusing on current and novel molecular tests such as polymerase chain reaction (PCR), digital PCR, high-resolution melt (HRM), and metagenomics/next generation sequencing (mNGS)., Expert Opinion: PCR is highly sensitive and specific, although performance can be impacted by prior/concurrent antifungal use. PCR assays can identify mutations associated with antifungal resistance, non-Aspergillus mold infections, and infections from endemic fungi. HRM is a rapid and highly sensitive diagnostic modality that can identify a wide range of fungal pathogens, including down to the species level, but multiplex assays are limited and HRM is currently unavailable in most healthcare settings, although universal HRM is working to overcome this limitation. mNGS offers a promising approach for rapid and hypothesis-free diagnosis of a wide range of fungal pathogens, although some drawbacks include limited access, variable performance across platforms, the expertise and costs associated with this method, and long turnaround times in real-world settings.
- Published
- 2023
- Full Text
- View/download PDF
22. Epidemiology, management and outcomes of Cryptococcus gattii infections: A 22-year cohort.
- Author
-
O'Hern JA, Koenen A, Janson S, Hajkowicz KM, Robertson IK, Kidd SE, Baird RW, Tong SY, Davis JS, Carson P, Currie BJ, and Ralph AP
- Subjects
- Humans, Adult, Antifungal Agents therapeutic use, Retrospective Studies, Cohort Studies, Northern Territory, Cryptococcosis drug therapy, Cryptococcosis epidemiology, Cryptococcus gattii
- Abstract
Background: Cryptococcus gattii is a globally endemic pathogen causing disease in apparently immune-competent hosts. We describe a 22-year cohort study from Australia's Northern Territory to evaluate trends in epidemiology and management, and outcome predictors., Methods: A retrospective cohort study of all C. gattii infections at the northern Australian referral hospital 1996-2018 was conducted. Cases were defined as confirmed (culture-positive) or probable. Demographic, clinical and outcome data were extracted from medical records., Results: 45 individuals with C. gattii infection were included: 44 Aboriginal Australians; 35 with confirmed infection; none HIV positive out of 38 tested. Multifocal disease (pulmonary and central nervous system) occurred in 20/45 (44%). Nine people (20%) died within 12 months of diagnosis, five attributed directly to C. gattii. Significant residual disability was evident in 4/36 (11%) survivors. Predictors of mortality included: treatment before the year 2002 (4/11 versus 1/34); interruption to induction therapy (2/8 versus 3/37) and end-stage kidney disease (2/5 versus 3/40). Prolonged antifungal therapy was the standard approach in this cohort, with median treatment duration being 425 days (IQR 166-715). Ten individuals had adjunctive lung resection surgery for large pulmonary cryptococcomas (median diameter 6cm [range 2.2-10cm], versus 2.8cm [1.2-9cm] in those managed non-operatively). One died post-operatively, and 7 had thoracic surgical complications, but ultimately 9/10 (90%) treated surgically were cured compared with 10/15 (67%) who did not have lung surgery. Four patients were diagnosed with immune reconstitution inflammatory syndrome which was associated with age <40 years, brain cryptococcomas, high cerebrospinal fluid pressure, and serum cryptococcal antigen titre >1:512., Conclusion: C. gattii infection remains a challenging condition but treatment outcomes have significantly improved over 2 decades, with eradication of infection the norm. Adjunctive surgery for the management of bulky pulmonary C. gattii infection appears to increase the likelihood of durable cure and likely reduces the required duration of antifungal therapy., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests:Dr. KH has received advisory board fees and grant support from Gilead Sciences. The authors have no other conflicts to declare., (Copyright: © 2023 O’Hern et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
23. Fungal Nomenclature: Managing Change is the Name of the Game.
- Author
-
Kidd SE, Abdolrasouli A, and Hagen F
- Abstract
Fungal species have undergone and continue to undergo significant nomenclatural change, primarily due to the abandonment of dual species nomenclature in 2013 and the widespread application of molecular technologies in taxonomy allowing correction of past classification errors. These have effected numerous name changes concerning medically important species, but by far the group causing most concern are the Candida yeasts. Among common species, Candida krusei , Candida glabrata , Candida guilliermondii , Candida lusitaniae , and Candida rugosa have been changed to Pichia kudriavzevii , Nakaseomyces glabrata , Meyerozyma guilliermondii , Clavispora lusitaniae , and Diutina rugosa , respectively. There are currently no guidelines for microbiology laboratories on implementing changes, and there is ongoing concern that clinicians will dismiss or misinterpret laboratory reports using unfamiliar species names. Here, we have outlined the rationale for name changes across the major groups of clinically important fungi and have provided practical recommendations for managing change., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
- Published
- 2023
- Full Text
- View/download PDF
24. Six- and 12-month functional outcomes among patients with confirmed acute flaccid myelitis (AFM) with onset in 2018, United States.
- Author
-
Lopez AS, Kidd S, Yee E, Dooling K, and Routh JA
- Subjects
- Child, Humans, United States, Lower Extremity, Neuromuscular Diseases complications, Myelitis, Central Nervous System Viral Diseases
- Abstract
Purpose: Acute flaccid myelitis (AFM), an uncommon but serious neurologic condition, primarily affects children, and can progress quickly to paralysis and respiratory failure. Data on long-term outcomes of patients with AFM are limited. This study reports on functional status through 12 months for AFM patients who became ill in 2018 in the United States., Methods: Health departments collected information on outcomes at 6 and 12 months after onset of AFM using a standardized form that asked patients or their parents/guardians about functional status. Analyses were restricted to confirmed cases., Results: Of the 238 confirmed AFM cases reported to CDC in 2018, 90 (38%) had assessments at 6 months, 82 (34%) at 12 months, and 49 (21%) at both 6 and 12 months. Among the 49 patients with data at both time points, the proportion of patients reporting significant or severe impairment at 6 months ranged from 2% to 59% depending on the outcome. Although proportions decreased by 12 months and ranged from 2% to 51%, most patients had some impairment at 12 months. No deaths were reported., Conclusion: Six- and 12-month outcomes in patients with onset of AFM in 2018 span a wide range of functionality, particularly of upper and lower extremities. Importantly, improvement appears to occur over time in some patients.
- Published
- 2023
- Full Text
- View/download PDF
25. Evaluation of a custom Sensititre YeastOne plate for susceptibility testing of isavuconazole and other antifungals against clinically relevant yeast and mould species in three Australian diagnostic mycology laboratories.
- Author
-
Halliday CL, Weeks K, Farac K, Alexiou H, Green W, Lopez R, Sarun Y, Weldhagen GF, Hardiman R, Chen SC, and Kidd SE
- Subjects
- Humans, Mycology, Laboratories, Australia, Microbial Sensitivity Tests, Antifungal Agents pharmacology, Saccharomyces cerevisiae
- Abstract
This study aimed to validate the performance of the custom formulated Sensititre YeastOne One (SYO) microdilution plate which includes isavuconazole (AUSNMRC1) to perform susceptibility testing on clinically relevant yeast and mould species across three Australian reference laboratories. The minimum inhibitory concentration (MIC) results were compared with the IVD approved SYO YO10 microdilution plate and isavuconazole gradient strips. A total of 127 isolates were tested on both the YO10 and AUSNMRC1 plates. The overall essential agreement (EA) and categorical agreement (CA) for the eight common drugs was 99.9% and 98.8%, respectively. The EA was 96.9% for the isavuconazole MICs obtained using the AUSNMRC1 plate and gradient strip. The MIC results for all nine antifungals on the AUSNMRC1 panel were highly reproducible for all quality control and reference strains and the overall EA and CA for 45 clinical strains tested across all three participating laboratories were >93% and 94.1%, respectively. These findings demonstrate the SYO AUSNMRC1 plate provides a commercial means to determine isavuconazole MICs by broth microdilution testing., (Copyright © 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. Wastewater Testing and Detection of Poliovirus Type 2 Genetically Linked to Virus Isolated from a Paralytic Polio Case - New York, March 9-October 11, 2022.
- Author
-
Ryerson AB, Lang D, Alazawi MA, Neyra M, Hill DT, St George K, Fuschino M, Lutterloh E, Backenson B, Rulli S, Ruppert PS, Lawler J, McGraw N, Knecht A, Gelman I, Zucker JR, Omoregie E, Kidd S, Sugerman DE, Jorba J, Gerloff N, Ng TFF, Lopez A, Masters NB, Leung J, Burns CC, Routh J, Bialek SR, Oberste MS, and Rosenberg ES
- Subjects
- Adult, Humans, New York epidemiology, United States, Wastewater, Poliomyelitis diagnosis, Poliomyelitis epidemiology, Poliomyelitis prevention & control, Poliovirus genetics, Poliovirus Vaccine, Oral adverse effects
- Abstract
In July 2022, a case of paralytic poliomyelitis resulting from infection with vaccine-derived poliovirus (VDPV) type 2 (VDPV2)
§ was confirmed in an unvaccinated adult resident of Rockland County, New York (1). As of August 10, 2022, poliovirus type 2 (PV2)¶ genetically linked to this VDPV2 had been detected in wastewater** in Rockland County and neighboring Orange County (1). This report describes the results of additional poliovirus testing of wastewater samples collected during March 9-October 11, 2022, and tested as of October 20, 2022, from 48 sewersheds (the community area served by a wastewater collection system) serving parts of Rockland County and 12 surrounding counties. Among 1,076 wastewater samples collected, 89 (8.3%) from 10 sewersheds tested positive for PV2. As part of a broad epidemiologic investigation, wastewater testing can provide information about where poliovirus might be circulating in a community in which a paralytic case has been identified; however, the most important public health actions for preventing paralytic poliomyelitis in the United States remain ongoing case detection through national acute flaccid myelitis (AFM) surveillance†† and improving vaccination coverage in undervaccinated communities. Although most persons in the United States are sufficiently immunized, unvaccinated or undervaccinated persons living or working in Kings, Orange, Queens, Rockland, or Sullivan counties, New York should complete the polio vaccination series as soon as possible., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Kirsten St. George and Meghan Fuschino report institutional support from ThermoFisher; royalty-generating collaborative research agreement with Zeptometrix, with payments to institution; and receipt of digital polymerase chain reaction equipment for public health testing purposes from QIAgen. Nancy McGraw reports an uncompensated leadership in the New York State Association of County Health Officials. Andrew Knecht reports uncompensated membership on the editorial board of the American Journal of Preventive Medicine–Focus. Daniel Lang reports uncompensated membership on the New York State Water Quality Council. No other potential conflicts of interest were disclosed.- Published
- 2022
- Full Text
- View/download PDF
27. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater-New York, June-August 2022.
- Author
-
Link-Gelles R, Lutterloh E, Ruppert PS, Backenson PB, St George K, Rosenberg ES, Anderson BJ, Fuschino M, Popowich M, Punjabi C, Souto M, McKay K, Rulli S, Insaf T, Hill D, Kumar J, Gelman I, Jorba J, Ng TFF, Gerloff N, Masters NB, Lopez A, Dooling K, Stokley S, Kidd S, Oberste MS, and Routh J
- Subjects
- Humans, Infant, New York, Public Health, Wastewater, Poliomyelitis diagnosis, Poliomyelitis prevention & control, Poliovirus
- Published
- 2022
- Full Text
- View/download PDF
28. Public Health Response to a Case of Paralytic Poliomyelitis in an Unvaccinated Person and Detection of Poliovirus in Wastewater - New York, June-August 2022.
- Author
-
Link-Gelles R, Lutterloh E, Schnabel Ruppert P, Backenson PB, St George K, Rosenberg ES, Anderson BJ, Fuschino M, Popowich M, Punjabi C, Souto M, McKay K, Rulli S, Insaf T, Hill D, Kumar J, Gelman I, Jorba J, Ng TFF, Gerloff N, Masters NB, Lopez A, Dooling K, Stokley S, Kidd S, Oberste MS, and Routh J
- Subjects
- Humans, New York epidemiology, Public Health, SARS-CoV-2, Wastewater, COVID-19, Poliomyelitis epidemiology, Poliomyelitis prevention & control, Poliovirus, Poliovirus Vaccine, Oral adverse effects
- Abstract
On July 18, 2022, the New York State Department of Health (NYSDOH) notified CDC of detection of poliovirus type 2 in stool specimens from an unvaccinated immunocompetent young adult from Rockland County, New York, who was experiencing acute flaccid weakness. The patient initially experienced fever, neck stiffness, gastrointestinal symptoms, and limb weakness. The patient was hospitalized with possible acute flaccid myelitis (AFM). Vaccine-derived poliovirus type 2 (VDPV2) was detected in stool specimens obtained on days 11 and 12 after initial symptom onset. To date, related Sabin-like type 2 polioviruses have been detected in wastewater* in the patient's county of residence and in neighboring Orange County up to 25 days before (from samples originally collected for SARS-CoV-2 wastewater monitoring) and 41 days after the patient's symptom onset. The last U.S. case of polio caused by wild poliovirus occurred in 1979, and the World Health Organization Region of the Americas was declared polio-free in 1994. This report describes the second identification of community transmission of poliovirus in the United States since 1979; the previous instance, in 2005, was a type 1 VDPV (1). The occurrence of this case, combined with the identification of poliovirus in wastewater in neighboring Orange County, underscores the importance of maintaining high vaccination coverage to prevent paralytic polio in persons of all ages., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest.
- Published
- 2022
- Full Text
- View/download PDF
29. Candida auris PCR for high-throughput infection control screening.
- Author
-
Crawford LC, Kidd SE, Anninos TM, Turra M, and Weldhagen GF
- Subjects
- Animals, Antifungal Agents therapeutic use, Candida genetics, Candida auris, Infection Control methods, Real-Time Polymerase Chain Reaction methods, Real-Time Polymerase Chain Reaction veterinary, Candidiasis microbiology, Candidiasis veterinary
- Abstract
Candida auris has significant implications for infection control due to its multidrug resistance and spread in healthcare settings. Current culture-based screening methods are laborious and risk muco-cutaneous colonisation of laboratory staff. We describe the adaptation of a published real-time PCR for the identification of C. auris in skin swabs for high-throughput infection control screening. Two published primer and probe sets were analysed utilising serial 10-fold dilutions of 15 C. auris strains to assess the PCR limit of detection. One primer and probe set was compatible with our laboratory workflow and was selected for further development yielding a limit of detection of 1 colony forming unit per reaction. Non-C. auris isolates as well as routine skin swabs (n = 100) were tested by culture and PCR to assess specificity, where no cross-reactivity was detected. Skin swabs from a proven C. auris case (n = 6) were all both culture positive and PCR positive, while surveillance swabs from close contacts (n = 46) were all both culture negative and PCR negative. Finally, the use of a lysis buffer comprising 4 m guanidinium thiocyanate rendered swab-equivalent quantities of C. auris non-viable, providing assurance of the safety benefit of PCR over culture. The development of a PCR assay for high-throughput infection control screening is a promising method for rapid detection of C. auris with utility in an outbreak setting., Lay Summary: Candida auris, a difficult to treat yeast-like fungus, has spread through healthcare facilities globally, posing a serious threat to the health of patients. We evaluated a PCR-based method suitable for screening large numbers of patient samples to rapidly and accurately detect C. auris., (© The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2022
- Full Text
- View/download PDF
30. Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators.
- Author
-
Burley R, Hewer RC, Teall M, Dickson L, Ossola B, Russell S, Bender C, Cheung T, Powell JAC, Xu X, Brice NL, Otter L, Arimont M, Kidd SL, Vidal D, Dale JW, Mervin L, Sore HF, Mateu N, Lakshminarayana N, Dawson LA, Carlton M, and Bürli RW
- Subjects
- Allosteric Regulation drug effects, Dose-Response Relationship, Drug, Humans, Molecular Structure, Pyrimidines chemical synthesis, Pyrimidines chemistry, Receptors, G-Protein-Coupled metabolism, Structure-Activity Relationship, Pyrimidines pharmacology, Receptors, G-Protein-Coupled agonists
- Abstract
We report a significant decrease in transcription of the G protein-coupled receptor GPR39 in striatal neurons of Parkinson's disease patients compared to healthy controls, suggesting that a positive modulator of GPR39 may beneficially impact neuroprotection. To test this notion, we developed various structurally diverse tool molecules. While we elaborated on previously reported starting points, we also performed an in silico screen which led to completely novel pharmacophores. In vitro studies indicated that GPR39 agonism does not have a profound effect on neuroprotection., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
31. Attitudes of Australasian Clinicians and Laboratory Staff to Changing Fungal Nomenclature: Has Mycological Correctness Really Gone Mad?
- Author
-
Kidd SE, Halliday CL, Haremza E, Gardam DJ, Chen SCA, and Elvy JA
- Subjects
- Attitude, Attitude of Health Personnel, Australia, Fungi genetics, Humans, Terminology as Topic, Fungi classification, Laboratory Personnel psychology, Physicians psychology
- Abstract
Fungal nomenclature changes have been a regular occurrence in recent years, eliciting heated debate on whether such changes will confuse clinicians and harm patients. We conducted surveys of Australasian laboratory staff and clinicians to assess attitudes, practices, and concerns regarding nomenclatural change. The majority of respondents to both surveys were aware of fungal nomenclatural changes (93.5% laboratories, 79.7% clinicians); 72.8% of laboratories had already implemented nomenclature changes, and 68.7% of clinicians recalled receiving at least one laboratory report utilizing updated fungal nomenclature. The vast majority of clinicians (94%) both within and outside of infection specialties supported laboratories reporting updated species names with inclusion of the previous species name. The importance of including the previous name on reports was demonstrated by 73.3% of clinicians viewing " Nakaseomyces glabrata (formerly Candida glabrata)" as clinically significant, versus only 38.2% viewing " Pichia kudriavzeveii " as significant in the absence of its former name. When asked about reporting practices, 73.9% of laboratories would report a Candida krusei isolate as " Pichia kudriavzeveii (formerly Candida krusei)," with the rest reporting as "Candida krusei " (21.7%) or " Pichia kudriavzeveii" (1.1%) without further explanation. Laboratory concerns included clinicians being confused by reports, commonly used identification platforms continuing to use superseded species names, education of staff, and delays in updating species codes in laboratory information systems. Adopting fungal name changes appears to be well supported by laboratories and clinicians in Australia and New Zealand, and can be achieved safely and unambiguously provided the former name is included on reports. IMPORTANCE Recent changes in fungal species names have been contentious, eliciting heated debate on social media. Despite available recommendations on adapting to the changes, concerns include clinicians dismissing pathogens as contaminants with patient harm as a result, and disruption of the literature. Such concerns are understandable, but are not supported by evidence and may represent a vocal minority. This survey of Australasian laboratories and clinicians assesses attitudes and practices relating to changes in fungal nomenclature and found that there is overwhelming support for adopting nomenclature changes.
- Published
- 2022
- Full Text
- View/download PDF
32. Candida auris susceptibility on surfaces coated with the antifungal drug caspofungin.
- Author
-
Lamont-Friedrich SJ, Kidd SE, Giles C, Griesser HJ, and Coad BR
- Subjects
- Animals, Drug Resistance, Fungal, Infection Control, Antifungal Agents pharmacology, Candida auris drug effects, Caspofungin pharmacology
- Abstract
Candida auris is known to survive for weeks on solid material surfaces. Its longevity contributes to medical device contamination and spread through healthcare facilities. We fabricated antifungal surface coatings by coating plastic and glass surfaces with a thin polymer layer to which the antifungal drug caspofungin was covalently conjugated. Caspofungin-susceptible and -resistant C. auris strains were inhibited on these surfaces by 98.7 and 81.1%, respectively. Cell viability studies showed that this inhibition was fungicidal. Our findings indicate that C. auris strains can be killed on contact when exposed to caspofungin that is reformulated as a covalently-bound surface layer., Lay Summary: Candida auris is pathogenic, multidrug resistant yeast with the ability to survive on surfaces and remain transmissible for long periods of time in healthcare settings. In this study, we have prepared an antifungal surface coating and demonstrated its ability to kill adhering C. auris cells on contact., (© The Author(s) 2021. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2021
- Full Text
- View/download PDF
33. National Surveillance for Acute Flaccid Myelitis - United States, 2018-2020.
- Author
-
Kidd S, Yee E, English R, Rogers S, Emery B, Getachew H, Routh JA, and Lopez AS
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Male, United States epidemiology, Central Nervous System Viral Diseases epidemiology, Myelitis epidemiology, Neuromuscular Diseases epidemiology, Population Surveillance
- Abstract
Acute flaccid myelitis (AFM), a recognized complication of certain viral infections, is a serious neurologic condition that predominantly affects previously healthy children and can progress rapidly, leading to respiratory insufficiency and permanent paralysis. After national AFM surveillance began in 2014, peaks in AFM cases were observed in the United States in 2014, 2016, and 2018 (1). On the basis of this biennial pattern, an increase in AFM was anticipated in 2020. To describe the epidemiology of confirmed AFM cases since 2018, demographic, clinical, and laboratory information collected as part of national AFM surveillance was reviewed. In 2018, a total of 238 confirmed AFM cases were reported to CDC, compared with 47 cases in 2019 and 32 in 2020. Enterovirus D68 (EV-D68) was detected in specimens from 37 cases reported in 2018, one case in 2019 and none in 2020. Compared with 2018, cases reported during 2019-2020 occurred in older children and were less frequently associated with upper limb involvement, febrile or respiratory prodromal illness, or cerebrospinal fluid (CSF) pleocytosis. These findings suggest that the etiologies of AFM in 2019 and 2020 differed from those in 2018. The absence of an increase in cases in 2020 reflects a deviation from the previously observed biennial pattern, and it is unclear when the next increase in AFM should be expected. Clinicians should continue to maintain vigilance and suspect AFM in any child with acute flaccid limb weakness, particularly in the setting of recent febrile or respiratory illness., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
- Published
- 2021
- Full Text
- View/download PDF
34. Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021.
- Author
-
Khanina A, Tio SY, Ananda-Rajah MR, Kidd SE, Williams E, Chee L, Urbancic K, and Thursky KA
- Subjects
- Consensus, Drug Resistance, Fungal, Humans, Immunocompromised Host, Antifungal Agents therapeutic use, Candidiasis, Invasive drug therapy, Candidiasis, Invasive epidemiology, Candidiasis, Invasive prevention & control
- Abstract
Invasive fungal diseases (IFD) are serious infections associated with high mortality, particularly in immunocompromised patients. The prescribing of antifungal agents to prevent and treat IFD is associated with substantial economic burden on the health system, high rates of adverse drug reactions, significant drug-drug interactions and the emergence of antifungal resistance. As the population at risk of IFD continues to grow due to the increased burden of cancer and related factors, the need for hospitals to employ antifungal stewardship (AFS) programmes and measures to monitor and prevent infection has become increasingly important. These guidelines outline the essential components, key interventions and metrics, which can help guide implementation of an AFS programme in order to optimise antifungal prescribing and IFD management. Specific recommendations are provided for quality processes for the prevention of IFD in the setting of outbreaks, during hospital building works, and in the context of Candida auris infection. Recommendations are detailed for the implementation of IFD surveillance to enhance detection of outbreaks, evaluate infection prevention and prophylaxis interventions and to allow benchmarking between hospitals. Areas in which information is still lacking and further research is required are also highlighted., (© 2021 Royal Australasian College of Physicians.)
- Published
- 2021
- Full Text
- View/download PDF
35. Complete clinical response to combined antifungal therapy in two cats with invasive fungal rhinosinusitis caused by cryptic Aspergillus species in section Fumigati .
- Author
-
Kay A, Boland L, Kidd SE, Beatty JA, Talbot JJ, and Barrs VR
- Abstract
Cryptic species in Aspergillus section Fumigati are increasingly reported to cause invasive aspergillosis in humans and animals. These infections are often refractory to treatment because of intrinsic antifungal resistance. We report two cases of invasive fungal rhinosinusitis in domestic cats caused by A. udagawae and A. felis . Clinical signs resolved after combined therapy including posaconazole, caspofungin and terbinafine. Both cases remained asymptomatic more than 2 years from initial presentation., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
36. Antifungal Susceptibility Testing and Identification.
- Author
-
Kidd SE, Crawford LC, and Halliday CL
- Subjects
- Antifungal Agents pharmacology, Endpoint Determination, Fungi classification, Fungi isolation & purification, Humans, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Antifungal Agents therapeutic use, Drug Resistance, Fungal, Fungi drug effects, Microbial Sensitivity Tests methods
- Abstract
The requirement for antifungal susceptibility testing is increasing given the availability of new drugs, increasing populations of individuals at risk for fungal infection, and emerging multiresistant fungi. Rapid and accurate fungal identification remains at the forefront of laboratory efforts to guide empiric therapy. Antifungal susceptibility testing methods have greatly improved, but are subject to variation in results between methods. Careful standardization, validation, and extensive training of users is essential to ensure susceptibility results are clinically useful and interpreted appropriately. Interpretive criteria for many drugs and species are still lacking, but this will continue to evolve., Competing Interests: Disclosure The authors have nothing to disclose., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Mycetoma caused by Microsporum canis in a patient with renal transplant: A case report and review of the literature.
- Author
-
Teo TSP, Crawford LC, Pilch WT, Carney B, Solanki N, Kidd SE, and Warner MS
- Subjects
- Humans, Microsporum, Arthrodermataceae, Dermatomycoses, Kidney Transplantation, Mycetoma
- Abstract
Microsporum canis is a dermatophyte known to cause superficial skin infections. In immunocompromised patients, it can lead to invasive dermatophytosis. We present a case of biopsy-proven left knee mycetoma caused by M canis in a renal transplant patient. Identification of M canis was achieved via sequencing of the internal transcribed spacer regions. Treatment involved surgical debridement, oral posaconazole, and reduction in immunosuppression. In addition, we provide a review of current literature on invasive M canis infections., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
38. Prevalence of Self-reported Neurologic and Ocular Symptoms in Early Syphilis Cases.
- Author
-
Quilter LAS, de Voux A, Amiya RM, Davies E, Hennessy RR, Kerani RP, Madera R, Matthias J, Pearson VM, Walters JK, Wilson C, Kidd S, and Torrone E
- Subjects
- Humans, Prevalence, Self Report, Syphilis Serodiagnosis, Eye Infections, Bacterial diagnosis, Eye Infections, Bacterial epidemiology, Neurosyphilis diagnosis, Neurosyphilis epidemiology, Syphilis diagnosis, Syphilis epidemiology
- Abstract
Background: Neurosyphilis, a complication of syphilis, can occur at any stage of infection. Measuring the prevalence of neurosyphilis is challenging, and there are limited data on the prevalence of neurologic or ocular symptoms among patients with syphilis. We sought to describe the prevalence of neurologic and/or ocular symptoms among early syphilis (ES) cases and the clinical management of symptomatic cases enrolled in the STD Surveillance Network (SSuN) Neuro/Ocular Syphilis Surveillance project., Methods: Persons diagnosed with ES were selected for interviews based on current health department protocols in 5 participating SSuN jurisdictions from November 2016 through October 2017. All interviewed ES cases were screened for self-reported neurologic and/or ocular symptoms. Additional clinical information on diagnostic testing and treatment for cases concerning for neurosyphilis/ocular syphilis was obtained from providers., Results: Among 9123 patients with ES who were interviewed, 151 (1.7%; 95% confidence interval [CI], 1.4%-1.9%) reported ≥ 1 neurologic or ocular symptom. Of the 53 (35%) who underwent lumbar puncture, 22 (42%) had documented abnormal cerebrospinal fluid, of which 21 (95%) were treated for neurosyphilis/ocular syphilis. Among the remaining 98 symptomatic patients with no documented lumbar puncture (65%), 12 (12%) were treated for and/or clinically diagnosed with neurosyphilis/ocular syphilis., Conclusions: We observed a low prevalence of self-reported neurologic and/or ocular symptoms in interviewed ES cases. Approximately one-third of ES cases who self-reported symptoms underwent further recommended diagnostic evaluation. Understanding barriers to appropriate clinical evaluation is important to ensuring appropriate management of patients with possible neurologic and/or ocular manifestations of syphilis., (Published by Oxford University Press for the Infectious Diseases Society of America 2020.)
- Published
- 2021
- Full Text
- View/download PDF
39. Risk factors for candidaemia: A prospective multi-centre case-control study.
- Author
-
Keighley CL, Pope A, Marriott DJE, Chapman B, Bak N, Daveson K, Hajkowicz K, Halliday C, Kennedy K, Kidd S, Sorrell TC, Underwood N, van Hal S, Slavin MA, and Chen SC
- Subjects
- Aged, Antifungal Agents therapeutic use, Candidemia drug therapy, Case-Control Studies, Female, Humans, Male, Middle Aged, Neutropenia complications, Organ Transplantation adverse effects, Prospective Studies, Risk Factors, Tertiary Care Centers statistics & numerical data, Candida pathogenicity, Candidemia etiology
- Abstract
Objectives: Candidaemia carries a mortality of up to 40% and may be related to increasing complexity of medical care. Here, we determined risk factors for the development of candidaemia., Methods: We conducted a prospective, multi-centre, case-control study over 12 months. Cases were aged ≥18 years with at least one blood culture positive for Candida spp. Each case was matched with two controls, by age within 10 years, admission within 6 months, admitting unit, and admission duration at least as long as the time between admission and onset of candidaemia., Results: A total of 118 incident cases and 236 matched controls were compared. By multivariate analysis, risk factors for candidaemia included neutropenia, solid organ transplant, significant liver, respiratory or cardiovascular disease, recent gastrointestinal, biliary or urological surgery, central venous access device, intravenous drug use, urinary catheter and carbapenem receipt., Conclusions: Risk factors for candidaemia derive from the infection source, carbapenem use, host immune function and organ-based co-morbidities. Preventive strategies should target iatrogenic disruption of mucocutaneous barriers and intravenous drug use., (© 2020 Wiley-VCH GmbH.)
- Published
- 2021
- Full Text
- View/download PDF
40. New Names for Fungi of Medical Importance: Can We Have Our Cake and Eat It Too?
- Author
-
Kidd SE, Halliday CL, McMullan B, Chen SC, and Elvy J
- Subjects
- Diagnostic Tests, Routine, Humans, Fungi, Mycology
- Published
- 2021
- Full Text
- View/download PDF
41. Enterovirus D68-Associated Acute Flaccid Myelitis, United States, 2020.
- Author
-
Kidd S, Lopez AS, Konopka-Anstadt JL, Nix WA, Routh JA, and Oberste MS
- Subjects
- Child, Humans, Neuromuscular Diseases, United States epidemiology, Central Nervous System Viral Diseases, Enterovirus D, Human genetics, Enterovirus Infections epidemiology, Myelitis epidemiology, Myelitis etiology
- Abstract
Acute flaccid myelitis (AFM) is a serious neurologic condition that causes limb weakness or paralysis in previously healthy children. Since clusters of cases were first reported in 2014, nationwide surveillance has demonstrated sharp increases in AFM cases in the United States every 2 years, most occurring during late summer and early fall. Given this current biennial pattern, another peak AFM season is expected during fall 2020 in the United States. Scientific understanding of the etiology and the factors driving the biennial increases in AFM has advanced rapidly in the past few years, although areas of uncertainty remain. The Centers for Disease Control and Prevention and AFM partners are focused on answering key questions about AFM epidemiology and mechanisms of disease. This article summarizes the current understanding of AFM etiology and outlines priorities for surveillance and research as we prepare for a likely surge in cases in 2020.
- Published
- 2020
- Full Text
- View/download PDF
42. Vital Signs: Clinical Characteristics of Patients with Confirmed Acute Flaccid Myelitis, United States, 2018.
- Author
-
Kidd S, Lopez A, Nix WA, Anyalechi G, Itoh M, Yee E, Oberste MS, and Routh J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, United States epidemiology, Young Adult, Central Nervous System Viral Diseases diagnosis, Central Nervous System Viral Diseases epidemiology, Myelitis diagnosis, Myelitis epidemiology, Neuromuscular Diseases diagnosis, Neuromuscular Diseases epidemiology, Population Surveillance
- Abstract
Background: Acute flaccid myelitis (AFM) is a serious neurologic syndrome that affects mostly children and is characterized by the acute onset of limb weakness or paralysis. Since U.S. surveillance for AFM began in 2014, reported cases have peaked biennially. This report describes the clinical characteristics of AFM patients during 2018, the most recent peak year., Methods: Medical records from persons meeting AFM clinical criterion (acute onset of flaccid limb weakness) were submitted to CDC. Patients with confirmed AFM met the clinical criterion and had magnetic resonance imaging indicating spinal cord lesions largely restricted to gray matter and spanning one or more vertebral segments. Symptoms, physical findings, test and imaging results, and hospitalization data were abstracted and described., Results: Among 238 patients with confirmed AFM during 2018, median age was 5.3 years. Among the 238 patients, 205 (86%) had onset during August-November. Most (92%) had prodromal fever, respiratory illness, or both beginning a median of 6 days before weakness onset. In addition to weakness, common symptoms at clinical evaluation were gait difficulty (52%), neck or back pain (47%), fever (35%), and limb pain (34%). Among 211 who were outpatients when weakness began, most (76%) sought medical care within 1 day, and 64% first sought treatment at an emergency department. Overall, 98% of patients were hospitalized, 54% were admitted to an intensive care unit, and 23% required endotracheal intubation and mechanical ventilation., Conclusion: Clinicians should suspect AFM in children with acute flaccid limb weakness, especially during August-November and when accompanied by neck or back pain and a recent history of febrile respiratory illness. Increasing awareness in frontline settings such as emergency departments should aid rapid recognition and hospitalization for AFM., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. W. Allan Nix and M. Steven Oberste have been issued U.S. patent numbers 7,247,457 and 7,714,122 for kits including VP1 and VP3 nucleic acid molecules. W. Allan Nix has been issued U.S. patent number 8,048,639 for detection and identification of parechoviruses. No other potential conflicts of interest were disclosed.
- Published
- 2020
- Full Text
- View/download PDF
43. Divergent Synthesis of Novel Cylindrocyclophanes that Inhibit Methicillin-Resistant Staphylococcus aureus (MRSA).
- Author
-
Freudenreich JJ, Bartlett S, Robertson NS, Kidd SL, Forrest S, Sore HF, Galloway WRJD, Welch M, and Spring DR
- Subjects
- Anti-Bacterial Agents chemical synthesis, Anti-Bacterial Agents chemistry, Dose-Response Relationship, Drug, Microbial Sensitivity Tests, Molecular Structure, Stereoisomerism, Structure-Activity Relationship, Anti-Bacterial Agents pharmacology, Methicillin-Resistant Staphylococcus aureus drug effects
- Abstract
The cylindrocyclophanes are a family of macrocyclic natural products reported to exhibit antibacterial activity. Little is known about the structural basis of this activity due to the challenges associated with their synthesis or isolation. We hypothesised that structural modification of the cylindrocyclophane scaffold could streamline their synthesis without significant loss of activity. Herein, we report a divergent synthesis of the cylindrocyclophane core enabling access to symmetrical macrocycles by means of a catalytic, domino cross-metathesis-ring-closing metathesis cascade, followed by late-stage diversification. Phenotypic screening identified several novel inhibitors of methicillin-resistant Staphylococcus aureus. The most potent inhibitor has a unique tetrabrominated [7,7]paracyclophane core with no known counterpart in nature. Together these illustrate the potential of divergent synthesis using catalysis and unbiased screening methods in modern antibacterial discovery., (© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2020
- Full Text
- View/download PDF
44. C(sp 3 )-H arylation to construct all-syn cyclobutane-based heterobicyclic systems: a novel fragment collection.
- Author
-
Osberger TJ, Kidd SL, King TA, and Spring DR
- Abstract
All-syn fused cyclobutanes remain an elusive chemotype and thus present an interesting synthetic challenge. Herein, we report the successful application of Pd-catalysed C(sp3)-H arylation of cyclobutane compounds to generate all-syn heterobicyclic fragments using an innovative 'inside-out' approach. Through this strategy we generate a virtual collection of 90 fragments, which we demonstrate to have enhanced three-dimensionality and superior fragment-like properties compared to existing collections.
- Published
- 2020
- Full Text
- View/download PDF
45. Hydroxylated Rotenoids Selectively Inhibit the Proliferation of Prostate Cancer Cells.
- Author
-
Russell DA, Bridges HR, Serreli R, Kidd SL, Mateu N, Osberger TJ, Sore HF, Hirst J, and Spring DR
- Subjects
- Animals, Blood-Brain Barrier, Cattle, Cell Division drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Drug Screening Assays, Antitumor, Electron Transport Complex I drug effects, Humans, Male, Mitochondrial Membranes drug effects, Molecular Structure, Rotenone chemistry, Uncoupling Agents chemistry, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Prostatic Neoplasms drug therapy, Rotenone analogs & derivatives, Rotenone pharmacology, Uncoupling Agents pharmacology
- Abstract
Prostate cancer is one of the leading causes of cancer-related death in men. The identification of new therapeutics to selectively target prostate cancer cells is therefore vital. Recently, the rotenoids rotenone ( 1 ) and deguelin ( 2 ) were reported to selectively kill prostate cancer cells, and the inhibition of mitochondrial complex I was established as essential to their mechanism of action. However, these hydrophobic rotenoids readily cross the blood-brain barrier and induce symptoms characteristic of Parkinson's disease in animals. Since hydroxylated derivatives of 1 and 2 are more hydrophilic and less likely to readily cross the blood-brain barrier, 29 natural and unnatural hydroxylated derivatives of 1 and 2 were synthesized for evaluation. The inhibitory potency (IC
50 ) of each derivative against complex I was measured, and its hydrophobicity (Slog10 P) predicted. Amorphigenin ( 3 ), dalpanol ( 4 ), dihydroamorphigenin ( 5 ), and amorphigenol ( 6 ) were selected and evaluated in cell-based assays using C4-2 and C4-2B prostate cancer cells alongside control PNT2 prostate cells. These rotenoids inhibit complex I in cells, decrease oxygen consumption, and selectively inhibit the proliferation of prostate cancer cells, leaving control cells unaffected. The greatest selectivity and antiproliferative effects were observed with 3 and 5 . The data highlight these molecules as promising therapeutic candidates for further evaluation in prostate cancer models.- Published
- 2020
- Full Text
- View/download PDF
46. Detection and identification of dermatophyte fungi in clinical samples using a commercial multiplex tandem PCR assay.
- Author
-
Ross IL, Weldhagen GF, and Kidd SE
- Subjects
- Hand Dermatoses diagnosis, Humans, Onychomycosis diagnosis, Sensitivity and Specificity, Arthrodermataceae, Dermatomycoses diagnosis, Multiplex Polymerase Chain Reaction methods
- Abstract
We evaluated the performance of a commercial multiplex tandem polymerase chain reaction (PCR) for detection of dermatophytes and other fungi in skin and nail specimens by (1) testing a range of fungal and bacterial reference cultures, (2) retrospectively testing a set of skin and nail specimens with known microscopy and culture results, and (3) prospectively testing skin and nail specimens in parallel to microscopy and culture. The AusDiagnostics Dermatophytes and Other Fungi assay accurately detected and identified a range of common dermatophytes to species, species complex or genus level, as well as Candida, Aspergillus and Scopulariopsis spp. It was unable to detect uncommon dermatophytes such as Nannizzia fulva (previously Microsporum fulvum), and Paraphyton cookei (previously Microsporum cookei). PCR identified a dermatophyte in 25.9% of prospective specimens which were culture negative. Sensitivity, specificity, positive predictive value, and negative predictive value were highest where microscopy and PCR results were combined, versus microscopy and culture combined, which highlights the significant contribution of microscopy in the diagnostic pathway. This assay has the potential to reduce the workload and results turnaround time associated with culturing and identification of dermatophytes, although microscopy remains important., (Copyright © 2020 Royal College of Pathologists of Australasia. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
47. Demonstration of the utility of DOS-derived fragment libraries for rapid hit derivatisation in a multidirectional fashion.
- Author
-
Kidd SL, Fowler E, Reinhardt T, Compton T, Mateu N, Newman H, Bellini D, Talon R, McLoughlin J, Krojer T, Aimon A, Bradley A, Fairhead M, Brear P, Díaz-Sáez L, McAuley K, Sore HF, Madin A, O'Donovan DH, Huber KVM, Hyvönen M, von Delft F, Dowson CG, and Spring DR
- Abstract
Organic synthesis underpins the evolution of weak fragment hits into potent lead compounds. Deficiencies within current screening collections often result in the requirement of significant synthetic investment to enable multidirectional fragment growth, limiting the efficiency of the hit evolution process. Diversity-oriented synthesis (DOS)-derived fragment libraries are constructed in an efficient and modular fashion and thus are well-suited to address this challenge. To demonstrate the effective nature of such libraries within fragment-based drug discovery, we herein describe the screening of a 40-member DOS library against three functionally distinct biological targets using X-Ray crystallography. Firstly, we demonstrate the importance for diversity in aiding hit identification with four fragment binders resulting from these efforts. Moreover, we also exemplify the ability to readily access a library of analogues from cheap commercially available materials, which ultimately enabled the exploration of a minimum of four synthetic vectors from each molecule. In total, 10-14 analogues of each hit were rapidly accessed in three to six synthetic steps. Thus, we showcase how DOS-derived fragment libraries enable efficient hit derivatisation and can be utilised to remove the synthetic limitations encountered in early stage fragment-based drug discovery., Competing Interests: There are no conflicts to declare., (This journal is © The Royal Society of Chemistry.)
- Published
- 2020
- Full Text
- View/download PDF
48. Fsp 3 -rich and diverse fragments inspired by natural products as a collection to enhance fragment-based drug discovery.
- Author
-
Hanby AR, Troelsen NS, Osberger TJ, Kidd SL, Mortensen KT, and Spring DR
- Subjects
- Biological Products chemical synthesis, Molecular Structure, Small Molecule Libraries chemical synthesis, Biological Products chemistry, Drug Discovery, Small Molecule Libraries chemistry
- Abstract
Herein, we describe the natural product inspired synthesis of 38 complex small molecules based upon 20 unique frameworks suitable for fragment-based screening. Utilising an efficient strategy, two key building block diastereomers were harnessed to generate novel, three-dimensional fragments which each possess numerous synthetically accessible fragment growth positions.
- Published
- 2020
- Full Text
- View/download PDF
49. Characteristics of Patients with Acute Flaccid Myelitis, United States, 2015-2018.
- Author
-
McLaren N, Lopez A, Kidd S, Zhang JX, Nix WA, Link-Gelles R, Lee A, and Routh JA
- Subjects
- Adolescent, Age Factors, Central Nervous System Viral Diseases etiology, Child, Disease Outbreaks, Enterovirus D, Human isolation & purification, Enterovirus Infections complications, Female, Humans, Infant, Male, Myelitis etiology, Neuromuscular Diseases etiology, United States epidemiology, Young Adult, Central Nervous System Viral Diseases epidemiology, Myelitis epidemiology, Neuromuscular Diseases epidemiology
- Abstract
Observed peaks of acute flaccid myelitis (AFM) cases have occurred biennially since 2014 in the United States. We aimed to determine if AFM etiology differed between peak and nonpeak years, considering that clinical features of AFM differ by virus etiology. We compared clinical and laboratory characteristics of AFM cases that occurred during peak (2016 and 2018, n = 366) and nonpeak (2015 and 2017, n = 50) years. AFM patients in peak years were younger (5.2 years) than those in nonpeak years (8.3 years). A higher percentage of patients in peak years than nonpeak years had pleocytosis (86% vs. 60%), upper extremity involvement (33% vs. 16%), and an illness preceding limb weakness (90% vs. 62%) and were positive for enterovirus or rhinovirus RNA (38% vs. 16%). Enterovirus D68 infection was associated with AFM only in peak years. Our findings suggest AFM etiology differs between peak and nonpeak years.
- Published
- 2020
- Full Text
- View/download PDF
50. A New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
- Author
-
Kidd SE, Chen SC, Meyer W, and Halliday CL
- Abstract
Invasive fungal diseases (IFDs) present an increasing global burden in immunocompromised and other seriously ill populations, including those caused by pathogens which are inherently resistant or less susceptible to antifungal drugs. Early diagnosis encompassing accurate detection and identification of the causative agent and of antifungal resistance is critical for optimum patient outcomes. Many molecular-based diagnostic approaches have good clinical utility although interpretation of results should be according to clinical context. Where an IFD is in the differential diagnosis, panfungal PCR assays allow the rapid detection/identification of fungal species directly from clinical specimens with good specificity; sensitivity is also high when hyphae are seen in the specimen including in paraffin-embedded tissue. Aspergillus PCR assays on blood fractions have good utility in the screening of high risk hematology patients with high negative predictive value (NPV) and positive predictive value (PPV) of 94 and 70%, respectively, when two positive PCR results are obtained. The standardization, and commercialization of Aspergillus PCR assays has now enabled direct comparison of results between laboratories with commercial assays also offering the simultaneous detection of common azole resistance mutations. Candida PCR assays are not as well standardized with the only FDA-approved commercial system (T2Candida) detecting only the five most common species; while the T2Candida outperforms blood culture in patients with candidemia, its role in routine Candida diagnostics is not well defined. There is growing use of Mucorales-specific PCR assays to detect selected genera in blood fractions. Quantitative real-time Pneumocystis jirovecii PCRs have replaced microscopy and immunofluorescent stains in many diagnostic laboratories although distinguishing infection may be problematic in non-HIV-infected patients. For species identification of isolates, DNA barcoding with dual loci (ITS and TEF1 α) offer optimal accuracy while next generation sequencing (NGS) technologies offer highly discriminatory analysis of genetic diversity including for outbreak investigation and for drug resistance characterization. Advances in molecular technologies will further enhance routine fungal diagnostics., (Copyright © 2020 Kidd, Chen, Meyer and Halliday.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.